Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from vTv Therapeutics ( (VTVT) ).
On March 31, 2025, vTv Therapeutics announced the resumption of their Phase 3 trial for cadisegliatin, following a clinical hold lifted on March 14, 2025. The trial, aimed at developing the first oral adjunct therapy for type 1 diabetes, will now be expedited by reducing its duration from 12 to 6 months, potentially enhancing the company’s market position and offering significant benefits to stakeholders by addressing high unmet needs in diabetes management.
More about vTv Therapeutics
vTv Therapeutics is a company in the life sciences industry, focusing on pioneering oral drugs to treat chronic diseases, particularly type 1 diabetes. Their primary product in development is cadisegliatin, a liver-selective glucokinase activator intended to improve glycemic control and reduce hypoglycemia in diabetes patients.
YTD Price Performance: 27.84%
Average Trading Volume: 22,903
Technical Sentiment Signal: Sell
Current Market Cap: $55.34M
Find detailed analytics on VTVT stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue